The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIxico Regulatory News (IXI)

Share Price Information for Ixico (IXI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 8.125
Bid: 8.00
Ask: 8.25
Change: 0.00 (0.00%)
Spread: 0.25 (3.125%)
Open: 8.125
High: 8.125
Low: 8.125
Prev. Close: 8.125
IXI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director/PDMR Shareholding

15 Jan 2020 10:32

RNS Number : 8891Z
IXICO plc
15 January 2020
 

15 January 2020

 

IXICO plc

("IXICO" or the "Company")

 

Exercise of Options and PDMR Dealings

IXICO plc (AIM: IXI), the data analytics company delivering insights in neuroscience, announces that it received notification on 10 January 2020 that John Hall, SVP Corporate Development and PDMR, exercised 75,000 options with an exercise price of 34p.

 

The Company has also received notification on 10 January 2020 that Robin Wolz, SVP Research & Development and PDMR, exercised 83,882 options of which 45,176 were exercisable at 30.5p and 38,706 were exercisable at 34p. The 83,882 shares were sold to a third party at an average price of 87.6p.

 

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 

John James Hall

 

2

 

Reason for the notification

 

a)

 

Position/status

 

 

PDMR (SVP Corporate Development)

b)

 

Initial notification /Amendment

 

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

 

IXICO plc

b)

 

LEI

 

 

2138005M1F59O6HWSA97

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

 

a)

 

Description of the financial instrument, type of instrument

Ordinary Shares in IXICO plc

Identification code

GB00BCLY7L40

 

b)

 

Nature of the transaction

 

 

Exercise of options

c)

 

Price(s) and volume(s)

 

 

 

 

 

Exercise Price(s)

Volume(s)

 

 

34p

75,000

 

 

 

 

 

d)

 

Aggregated information

- Aggregated volume

75,000 shares

- Price

34p

e)

 

Date of the transaction

 

 

10/1/20

f)

 

Place of the transaction

 

 

N/A

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 

Robin Wolz

 

2

 

Reason for the notification

 

a)

 

Position/status

 

 

PDMR (SVP Research & Development)

b)

 

Initial notification /Amendment

 

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

 

IXICO plc

b)

 

LEI

 

 

2138005M1F59O6HWSA97

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

 

a)

 

Description of the financial instrument, type of instrument

Ordinary Shares in IXICO plc

Identification code

GB00BCLY7L40

 

b)

 

Nature of the transaction

 

 

Exercise of options

c)

 

Price(s) and volume(s)

 

 

 

 

 

Exercise Price(s)

Volume(s)

 

 

30.5p

45,176

 

 

34p

38,706

 

 

 

 

 

d)

 

Aggregated information

- Aggregated volume

83,882 shares

- Price

32.1p

e)

 

Date of the transaction

 

 

10/1/20

f)

 

Place of the transaction

 

 

N/A

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

 

a)

 

Name

 

 

Robin Wolz

 

 

2

 

Reason for the notification

 

 

a)

 

Position/status

 

 

PDMR (SVP Research & Development)

 

b)

 

Initial notification /Amendment

 

 

Initial notification

 

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

 

a)

 

Name

 

 

IXICO plc

 

b)

 

LEI

 

 

2138005M1F59O6HWSA97

 

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

 

 

a)

 

Description of the financial instrument, type of instrument

Ordinary Shares in IXICO plc

 

 

Identification code

GB00BCLY7L40

 

 

 

b)

 

Nature of the transaction

 

 

Sale

 

c)

 

Price(s) and volume(s)

 

 

 

 

 

 

Price(s) Date

Volume(s)

 

 

 

92p 10/1/20

18,395

 

 

 

90p 13/1/20

18,395

 

 

 

85p 13/1/20

47,092

 

 

 

 

 

 

 

d)

 

Aggregated information

 

 

- Aggregated volume

83,882 shares

 

 

- Price

87.6p

 

 

e)

 

Date of the transaction

 

 

10/1/20 and 13/1/20

 

f)

 

Place of the transaction

 

 

London Stock Exchange

 

 

IXICO plc

+44 (0) 20 3763 7498

Giulio Cerroni, Chief Executive Officer

Grant Nash, Chief Financial Officer

 

Cenkos Securities PLC (Nominated adviser and sole broker)

+44 (0) 20 7397 8900

Giles Balleny / Max Gould (Corporate Finance)

Michael F Johnson / Russell Kerr (Sales)

Optimum Strategic Communications

 +44 (0) 203 950 9144

Mary Clark / Supriya Mathur/Manel Mateus

ixico@optimumcomms.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHBELFFBFLXBBB
Date   Source Headline
8th Feb 202212:30 pmRNSHolding(s) in Company
8th Feb 20227:00 amRNSContract award worth circa £1.0m
31st Jan 20227:00 amRNSAppointment of Senior Therapeutic Advisor
26th Jan 20227:00 amRNSDementia collaboration
21st Jan 20227:00 amRNSNon-Executive Director Appointment
20th Jan 202210:50 amRNSResult of AGM
20th Jan 20227:00 amRNSHuntington’s disease contract update
10th Jan 20227:00 amRNSGrant of share options
7th Dec 20217:00 amRNSFinancial Results for the year ended 30 Sept 2021
22nd Nov 20217:00 amRNSNotice of Results
1st Nov 20216:08 pmRNSHolding(s) in Company
1st Nov 20217:00 amRNSNew contract worth >£1.0m
20th Oct 20214:27 pmRNSContract update
18th Oct 20217:00 amRNSTrading Update for year ended 30 September 2021
22nd Sep 20217:00 amRNSNew contract worth >$750k
20th Sep 20217:00 amRNSPhase II HD contract with new client worth >$500K
8th Sep 20217:00 amRNSPhase I MSA contract award worth >$500k
6th Aug 20217:00 amRNSTrading Update
23rd Jun 20213:32 pmRNSIssue of Equity
21st Jun 20212:31 pmRNSHolding(s) in Company
15th Jun 20217:00 amRNSFurther investment in Ixico plc
11th Jun 202111:35 amRNSHolding(s) in Company
25th May 20217:00 amRNSHalf yearly report to 31 March 2021
20th May 20217:00 amRNSPhase II Alzheimer’s disease contract award
19th May 20217:00 amRNSContract win for new neuroinflammatory disorder
11th May 20217:00 amRNSNotice of results
28th Apr 20217:00 amRNSContract win for new stroke study
26th Apr 20217:00 amRNSTrading update
19th Apr 20218:21 amRNSHolding(s) in Company
12th Apr 20214:00 pmRNSHolding(s) in Company
12th Apr 20217:00 amRNSInvestment in Ixico plc
1st Apr 20217:00 amRNSHolding(s) in Company
25th Mar 20219:14 amRNSPDMR Transaction
24th Mar 20219:05 amRNSSecond Price Monitoring Extn
24th Mar 20219:00 amRNSPrice Monitoring Extension
23rd Mar 20214:40 pmRNSSecond Price Monitoring Extn
23rd Mar 20214:35 pmRNSPrice Monitoring Extension
23rd Mar 20213:05 pmRNSHuntington’s disease Phase III contract updates
15th Mar 20214:41 pmRNSSecond Price Monitoring Extn
15th Mar 20214:35 pmRNSPrice Monitoring Extension
15th Mar 20212:06 pmRNSSecond Price Monitoring Extn
15th Mar 20212:00 pmRNSPrice Monitoring Extension
15th Mar 202111:06 amRNSSecond Price Monitoring Extn
15th Mar 202111:01 amRNSPrice Monitoring Extension
15th Mar 20217:00 amRNSCollaboration with Microsoft
10th Mar 20217:00 amRNSIXICO chosen for new Phase II AD study
2nd Mar 20217:00 amRNSIXICO selected by Cyclerion for a new AD study
1st Mar 20215:25 pmRNSExercise of Options; PDMR Dealing
1st Mar 20217:00 amRNSConference attendance and presentations
29th Jan 202110:19 amRNSPDMR Dealing

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.